Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 913 matching trials from the live ClinicalTrials.gov search.
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Interventions
Faricimab, Port Delivery System with Ranibizumab
Drug · Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more
Conditions
Age-Related Macular Degeneration
Interventions
FORESEE HOME
Device
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Toms River, New Jersey
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose, AR-13503 63.6 Dose
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Gilbert, Arizona • Beverly Hills, California • Walnut Creek, California + 3 more
Conditions
Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Interventions
ALK-001
Drug
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more
Recruiting No phase listed Observational Accepts healthy volunteers

Inherited Retinal Degenerative Disease Registry

NCT02435940
Conditions
Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome, Bassen-Kornzweig Syndrome, Batten Disease, Best Disease, Choroidal Dystrophy, Choroideremia, Cone Dystrophy, Cone-Rod Dystrophy, Congenital Stationary Night Blindness, Enhanced S-Cone Syndrome, Fundus Albipunctatus, Goldmann-Favre Syndrome, Gyrate Atrophy, Juvenile Macular Degeneration, Kearns-Sayre Syndrome, Leber Congenital Amaurosis, Refsum Syndrome, Retinitis Pigmentosa, Retinitis Punctata Albescens, Retinoschisis, Rod-Cone Dystrophy, Rod Dystrophy, Rod Monochromacy, Stargardt Disease, Usher Syndrome
Interventions
Not listed
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2037
U.S. locations
1
States / cities
Columbia, Maryland
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
APL-2, Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Bakersfield, California • Oxnard, California • Austin, Texas + 2 more
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Prism Vision Group
Other
Eligibility
65 Years to 90 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Edison, New Jersey
Conditions
Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Interventions
ALK-001, Placebo
Drug
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 11 more
Conditions
Macular Degeneration
Interventions
RO6867461
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Colorado Springs, Colorado • Baltimore, Maryland • Dallas, Texas + 2 more
Completed Phase 2 Interventional Results available

Carbidopa-levodopa in Neovascular AMD

NCT03022318
Conditions
Age-related Macular Degeneration
Interventions
carbidopa-levodopa 25-100 mg tablets
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Completed No phase listed Observational Accepts healthy volunteers Results available

Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)

NCT03322930
Conditions
Retinitis Pigmentosa, AMD
Interventions
Rod sensitivity
Diagnostic Test
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
10 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Terminated No phase listed Observational

Ocular Imaging Study Using Advanced OCT

NCT02827071
Conditions
Retinal Vascular Disorder, Macular Degeneration
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 115 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
OCU-10-C-110 for Injection
Drug
Lead sponsor
Ocugenix Corporation
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Carmel, Indiana • Abilene, Texas • Willow Park, Texas
Conditions
Neovascular Age-related Macular Degeneration
Interventions
2.0 mg OPT-302, 0.5 mg ranibizumab, Sham
Biological · Procedure
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
76
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 67 more
Completed Phase 2Phase 3 Interventional Results available

Phase 2/3 Study of ALK-001 in Geographic Atrophy

NCT03845582
Conditions
Geographic Atrophy, Age Related Macular Degeneration, AMD, Atrophy, Geographic
Interventions
ALK-001 oral capsule, Placebo oral capsule
Drug
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Lakewood, Colorado + 20 more
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Nidek MP-3
Device
Lead sponsor
Doheny Image Reading Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pasadena, California
Active, not recruiting No phase listed Observational

ForeseeHome NRich Registry

NCT05690880
Conditions
Age-Related Macular Degeneration
Interventions
Foresee Home
Device
Lead sponsor
Notal Vision Inc.
Industry
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Toms River, New Jersey
Enrolling by invitation No phase listed Observational

Implementation of the NEDS EyeCTester App

NCT04607369
Conditions
Optic Nerve Disease, Macular Disease, Visual Pathway Disorder
Interventions
EyeCTester
Device
Lead sponsor
Neuro-Eye Diagnostic Systems, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Bellaire, Texas
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 3 more
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Intravenous Daclizumab, Intravenous Infliximab, Observation, Oral Rapamycin
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 92 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Interventions
EXG102-031
Biological
Lead sponsor
Exegenesis Bio
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Reno, Nevada • Erie, Pennsylvania
Conditions
Wet Macular Degeneration
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
59
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more
Conditions
Age Related Macular Degeneration
Interventions
Longvida curcumin, placebo
Drug · Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration, Macular Atrophy, Retinal Degeneration, Eye Diseases
Interventions
Not listed
Lead sponsor
Complement Therapeutics
Industry
Eligibility
65 Years and older
Enrollment
234 participants
Timeline
2023 – 2025
U.S. locations
10
States / cities
Glendale, California • Mountain View, California • Carmel, Indiana + 7 more